Deals tracker: iRhythm to acquire VitalConnect
iRhythm is set to acquire VitalConnect, adding a transaction catalyst to the company’s growth story. The available data show strong revenue growth but continuing losses, leaving deal execution and the path to profitability as the key setup for IRTC.
iRhythm is set to acquire VitalConnect, according to the Deals Tracker item from Modern Healthcare.
The transaction adds a strategic catalyst to IRTC, which reported FY2025 revenue of $747.1M, up 26.2% YoY. The company also recorded a 70.6% gross margin, but remained unprofitable with a -6.0% net margin and $-1.39 diluted EPS.
That combination creates a clear bull case around broader connected-cardiac-monitoring scale and a bear case around integration, funding, and dilution risk.
The next signals are the definitive transaction terms, financing structure, regulatory or closing conditions, and any guidance for revenue, margins, or cash use after the deal.
The VitalConnect acquisition adds strategic upside but leaves deal terms, funding and profitability risk unresolved for IRTC.
The acquisition could expand IRTC’s connected-care platform. The existing financial profile is mixed: FY2025 revenue grew 26.2% YoY to $747.1M with a 70.6% gross margin, while net margin was -6.0% and diluted EPS was $-1.39.
A costly or equity-funded transaction, integration problems, or no improvement in the company’s losses would undermine the strategic case.
CoverageSource: modernhealthcare.com · Published here SAT, AUG 8 · 5:59 AM ET · the only report in this recordHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Price context does not establish that the story caused the move.
The strongest bull case is that VitalConnect broadens IRTC’s monitoring footprint and supports the company’s 26.2% YoY revenue growth trajectory without damaging its 70.6% gross margin.
The bear case is stronger on the missing facts: with IRTC still at a -6.0% net margin and $-1.39 diluted EPS, an undisclosed purchase price or financing structure could add execution and dilution risk before synergies are proven.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →